(S)-3-methylnonan-2-one | 20659-78-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-3-methylnonan-2-one
• 英文别名: (S)-3-methyl-nonan-2-one；(3S)-3-methylnonan-2-one
• CAS: 20659-78-3
• 化学式: C₁₀H₂₀O
• 分子量: 156.268
• InChiKey: BMLJPODSPMQJKF-VIFPVBQESA-N

物化性质

• 沸点：
  199.3±8.0 °C(Predicted)
• 密度：
  0.817±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正己醛 在 硫酸 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 24.0h， 生成 (S)-3-methylnonan-2-one
  参考文献：
  名称：

  Enantiodivergence in the reduction of α-methyl and α-halomethyl enones by microorganisms

  摘要：

  Enones (Z)-3-methyl-(Z)-3-chloromethyl- and (Z)-3-bromomethyl-4-R-3-buten-2-one (R = n-pentyl, phenyl, 2'- and 4'-chlorophenyl, 3'- and 4'-nitrophenyl, 4'-methoxyphenyl) were synthesized and subjected to reduction by the microorganisms Saccharomyces cerevisiae and Geotrichum candidum. Whereas the bioreduction of 3-methy-4-R-3-buten-2-ones afforded the corresponding (S)-4-R-3-methybutan-2-ones, the bioreduction of 3-chloromethyl- and 3-bromomethyl-4-R-3-buten-2-ones afforded the corresponding (R)-4-R-3-methybutan-2-ones. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2013.07.007

文献信息

• Seebach,D. et al., Angewandte Chemie, 1968, vol. 80, p. 618 - 619
  作者：Seebach,D. et al.

  DOI：——

  日期：——
• INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF
  申请人：Provid Pharmaceuticals, Inc.

  公开号：EP1605963B1

  公开（公告）日：2011-11-16
• DOUBLE-ACYLATED GLP-1 DERIVATIVES
  申请人：Novo Nordisk A/S

  公开号：US20140088005A1

  公开（公告）日：2014-03-27

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K 27 , and the second K residue is designated K T ; which derivative comprises two albumin binding moieties attached to K 27 and K T , respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH 2 ) x —CO— and HOOC—C 6 H 4 -0-(CH 2 ) y —CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH 2 ) 2 —(O—(CH 2 ) 2 ) k —O—(CH 2 ) n —CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.
• US9266940B2
  申请人：——

  公开号：US9266940B2

  公开（公告）日：2016-02-23
• Enantiodivergence in the reduction of α-methyl and α-halomethyl enones by microorganisms
  作者：Bruno R.S. de Paula、Dávila S. Zampieri、J. Augusto R. Rodrigues、Paulo J.S. Moran

  DOI：10.1016/j.tetasy.2013.07.007

  日期：2013.9

  Enones (Z)-3-methyl-(Z)-3-chloromethyl- and (Z)-3-bromomethyl-4-R-3-buten-2-one (R = n-pentyl, phenyl, 2'- and 4'-chlorophenyl, 3'- and 4'-nitrophenyl, 4'-methoxyphenyl) were synthesized and subjected to reduction by the microorganisms Saccharomyces cerevisiae and Geotrichum candidum. Whereas the bioreduction of 3-methy-4-R-3-buten-2-ones afforded the corresponding (S)-4-R-3-methybutan-2-ones, the bioreduction of 3-chloromethyl- and 3-bromomethyl-4-R-3-buten-2-ones afforded the corresponding (R)-4-R-3-methybutan-2-ones. (C) 2013 Elsevier Ltd. All rights reserved.